Hosted on MSN11mon
Piper downgrades Achilles to neutral, cites latest dataPiper Sandler has downgraded Achilles Therapeutics (NASDAQ:ACHL) to neutral in the wake of additional Phase 1/2 data from its CHIRON and THETIS studies for its precision T cell therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback